Quest Diagnostics Inc Stock Price, News & Analysis

Guardant Health (NASDAQ: GH) and Quest Diagnostics (NYSE: DGX) have announced a strategic collaboration to expand access to Guardant's Shield™ blood-based colorectal cancer screening test across the United States. The Shield test, which is FDA-approved for average-risk adults aged 45 and older, will be available through Quest's extensive network of approximately 650,000 clinician and hospital accounts.

The partnership will enable physicians to order Shield directly through their existing Quest accounts and EHR systems. Patients will have access to blood draws at Quest's 2,000 service centers and 6,000 in-office phlebotomists. The test is expected to launch through Quest in Q1 2026. Shield is currently covered by Medicare and the Veterans Affairs Community Care Network.

Quest Diagnostics (NYSE: DGX) has announced a groundbreaking collaboration with Epic to enhance laboratory testing experiences across the United States. This first-of-its-kind partnership will serve as the foundation for Project Nova, Quest's initiative to improve customer-facing processes.

The implementation will leverage Epic's comprehensive Diagnostic Enterprise system, including Aura, Beaker Laboratory, Care Everywhere, MyChart, and Resolute Professional Billing & Claims across Quest's national laboratory network. The multi-year project aims to streamline account onboarding, lab ordering, results reporting, appointment scheduling, and billing services at Quest's 2,000 patient service centers.

Quest Diagnostics (NYSE:DGX) subsidiary Haystack Oncology announced a research collaboration with Rutgers Cancer Institute to evaluate Haystack MRD®, a ctDNA minimal residual disease test, for optimizing post-surgery treatment in stage II/III non-small cell lung cancer (NSCLC) patients.

The phase II study, dubbed MRD-PORT Trial (NCT06979661), will assess if residual tumor DNA detection post-surgery can guide radiation and systemic therapy decisions. The collaboration follows a 2023 study evaluating the test in early-stage triple-negative breast cancer patients.

Recent research published in NEJM demonstrated Haystack MRD's ability to identify clinical complete response 1.4 months faster than imaging tests. The test received FDA Breakthrough Device Designation in August 2025 for identifying MRD-positive stage II colorectal cancer patients.

Quest Diagnostics (NYSE:DGX) has partnered with WHOOP to integrate clinical laboratory testing services into the WHOOP app through a new feature called WHOOP Advanced Labs, launching fall 2025. The collaboration will enable WHOOP members to purchase Quest lab tests, schedule appointments, and receive results directly through the app.

The integration will analyze various biomarkers including metabolism, hormones, inflammation, cardiovascular health, and nutrient status. Quest will provide testing through its network of approximately 2,000 patient service centers across the U.S., along with mobile phlebotomy services. A third-party provider will review test requests, manage orders, deliver results, and offer phone consultations.

Quest Diagnostics (NYSE:DGX), a diagnostic information services leader, announced that Executive Vice President and CFO Sam Samad will participate in the Jefferies Healthcare Services Conference in Nashville. The presentation is scheduled for September 29, 2025, at 4:35 p.m. ET.

The fireside chat and Q&A session will be available via live webcast on Quest's investor relations website. An archived version will be accessible within 24 hours after the event until October 24, 2025.

Quest Diagnostics (NYSE: DGX) has launched an advanced pharmacogenomic (PGx) laboratory test service to help healthcare providers optimize drug prescriptions based on patients' genetic profiles. The service analyzes 17 genes and 4 HLA alleles to provide insights across multiple medical specialties including psychiatry, neurology, cardiology, oncology, and others.

The comprehensive offering includes Quest-delivered reports with genotype and phenotypic response, along with medication guidance through Coriell Life Sciences' GeneDose LIVE platform. The service aims to prevent therapeutic failures, reduce adverse drug interactions, and minimize unnecessary drug costs. Patients can access testing at Quest's 2,000 patient service centers nationwide or through home collection services.

Quest Diagnostics (NYSE:DGX) released its 2025 Drug Testing Index, revealing concerning trends in workplace drug testing. The analysis of over 8 million drug tests shows that fentanyl positivity in random tests (1.13%) was 707% higher than in pre-employment tests (0.14%), suggesting increased on-the-job usage.

While overall workplace drug positivity slightly declined to 4.4% from 4.6%, the data showed that 60% of fentanyl-positive specimens also contained other drugs. Notably, marijuana co-positivity with fentanyl doubled since 2020 to 22%, while amphetamine co-positivity increased to 16% from 11%.

The report also highlighted that marijuana remains the most detected substance with 4.5% positivity in the general workforce, with concerning post-accident positivity rates of 7.3%. For-cause testing showed a 33.1% positivity rate, demonstrating ongoing workplace substance abuse challenges.

Quest Diagnostics (NYSE:DGX) and Corewell Health have announced a strategic joint venture to form Diagnostic Lab of Michigan, LLC. The partnership includes building a 100,000-square-foot state-of-the-art laboratory in Southfield, Michigan, featuring advanced technologies for automated microbiology and high-throughput molecular testing.

Under the agreement, Quest will hold 51% ownership while Corewell Health will retain 49%. Quest will manage Corewell Health's 21 hospital laboratories across Michigan through its Collaborative Lab Solutions program. The joint venture transaction is expected to complete in Q1 2026, with the new laboratory becoming operational in Q1 2027.

Quest Diagnostics (NYSE:DGX) has received FDA Breakthrough Device Designation for its Haystack MRD® test, designed to identify minimal residual disease (MRD) in stage II colorectal cancer patients after surgery. The test helps determine which patients might benefit from adjuvant therapy.

The designation follows Quest's launch of a clinical laboratory-developed version of Haystack MRD in late 2024. The test utilizes circulating tumor DNA (ctDNA) technology to detect residual or recurrent cancer from solid tumors. The Breakthrough Device Program aims to accelerate development and review of medical devices for life-threatening conditions while maintaining FDA safety standards.